Consequently, pharmaceutical modulation of RGS5 activity by small molecule approaches, as has been shown for RGS4 (Roman et al, 2007), may have great clinical relevance with respect to stimulating arteriogenesis or counteracting neointima formation during arteriosclerosis or in-stent restenosis. This evidence concerns the gene RGS5 and arteriosclerosis disorder.